GenoGra, a B2B start-up that is redefining the standards of genomic analysis, announces that it has closed a €1 million pre-seed investment round. The transaction is led by Maia Ventures (Praesidium SA) through the Maia I fund, in which the EIF participates through the InvestEU Fund programme. Also participating in the round are an industry business angel, PM Holding, and Terra Next, the acceleration programme dedicated to innovative start-ups and SMEs in the bioeconomy sector, the result of an initiative by CDP Venture Capital, with the participation of Intesa Sanpaolo Innovation Centre and Cariplo Factory.
“This round represents a strategic step forward for GenoGra,” said Guido Walter Di Donato, CEO and founder of the start-up (pictured with the team), in a statement. “With the support of investors who share our vision, we are ready to accelerate the development of the platform and demonstrate how pangenomics can radically improve the way we analyse and interpret genomic data. This revolution is necessary to fully understand the mechanisms underlying DNA and bring us closer to an increasingly complete reading of the genetic code.”
The start-up, founded by NECSTlab at the Politecnico di Milano and accelerated by Bocconi 4 Innovation, has developed the first pan-genomic analysis platform designed to optimise and simplify population genomics processes. Thanks to proprietary technology based on pan-genomic graphs, the platform delivers faster, more accurate and immediately usable results, drastically reducing analysis times. Strategic focus on the non-human market GenoGra’s go-to-market strategy involves an initial launch in the non-human segment, an area rich in opportunities in the agrifood, livestock, energy and industrial microorganism sectors. The technology is designed to be scalable and accessible to these market segments, offering advanced genomic analysis tools to sectors that have traditionally had less access to solutions of this type.
The technological heart of GenoGra consists of high-performance proprietary software and interactive visualisation tools that define a new approach to genomic data analysis. The top-down approach to population genomics allows large amounts of genetic data to be analysed in order to compare different samples with each other. This makes it easier to identify genetic variants that are common to a population and understand how they are linked to observable characteristics, such as predisposition to certain diseases. All this opens up new horizons in the discovery of new biomarkers and in the advancement of medical research, geared towards precision medicine.
The funds raised will be used to launch the product for non-human applications and achieve product-market fit, in parallel with the certification and validation of applications in the human field. GenoGra also plans to significantly expand its team during 2026. The start-up is currently conducting pilot projects and proof of concept with various stakeholders, including universities, research centres, hospitals, diagnostic laboratories and companies in the agri-food and energy sectors.
ALL RIGHTS RESERVED ©